Skip to content
DataLookout
Menu

NCT03163368

Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors

StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 14 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 14 words
    • Study completion pushed from Jun 1, 2026 to Sep 1, 2027
  2. Minor Study completion date: Nov 1, 2025 to Jun 1, 2026v17
  3. Minor Primary completion date changed from estimate of Dec 30, 2023 to Dec 15, 2022
    • Study completion date: Jun 1, 2024 to Nov 1, 2025
    v15
  4. Notable Primary completion date: Dec 30, 2022 to Dec 30, 2023
    • Study completion date: Jun 1, 2023 to Jun 1, 2024
    v13
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Dec 1, 2022 to Dec 30, 2022
    • Site details revised
    v12
Show 8 earlier versionsHide 8 earlier versions
  1. Notable Primary completion date: Jun 1, 2022 to Dec 1, 2022
    • Study completion date: Dec 1, 2022 to Jun 1, 2023
    v11
  2. Notable Primary completion date: Dec 1, 2021 to Jun 1, 2022
    • Study completion date: Jun 1, 2022 to Dec 1, 2022
    v10
  3. Notable Primary completion date: Jun 1, 2021 to Dec 1, 2021
    • Study completion date: Dec 1, 2021 to Jun 1, 2022
    v9
  4. Notable Primary completion date: Dec 1, 2020 to Jun 1, 2021
    • Study completion date: Jun 1, 2021 to Dec 1, 2021
    v7
  5. Notable Primary completion date: Dec 1, 2019 to Dec 1, 2020
    • Study completion date: Jun 1, 2020 to Jun 1, 2021
    v5
  6. Notable Eligibility criteria expanded, about 4 words
    • Site contact updated
    v4
  7. Notable Primary completion date: Jan 1, 2019 to Dec 1, 2019
    • Eligibility criteria expanded, about 4 words
    • Study completion date: Jun 1, 2019 to Jun 1, 2020
    • Site contact updated
    v3
  8. Notable Phase: Not applicable to Early Phase 1
    • Eligibility criteria expanded, about 5 words
    • Interventions: Neoadjuvant stereotactic radiosurgery (Radiation) to Neoadjuvant stereotactic radiosurgery (Radiation), Neurosurgical resection (Procedure)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum tolerated dose (MTD)
Timeframe: 1 month after neurosurgery

Secondary (7)

Adverse events
Describe preliminary rates of image-complete resection
Describe preliminary rates of local tumor control
Describe preliminary rates of intracranial control
Describe preliminary rates of progression-free survival
Show 2 moreShow less
Describe preliminary rates of leptomeningeal spread
Describe preliminary rates of rate of salvage treatment

Arms and interventions

Neoadjuvant stereotactic radiosurgeryExperimental

Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.

Radiation: Neoadjuvant stereotactic radiosurgery

Procedures: Neurosurgical resection

Sites

1 site in 1 country

  • Cedars-Sinai Medical CenterLos Angeles, California, United States